Advertisement

Prognostic Biomarkers for Hepatocellular Carcinoma

  • Koh Rui Qi
  • Pek Mi Xue Michelle
  • Tan Min-HanEmail author
Conference paper

Abstract

Hepatocellular carcinoma (HCC) affects approximately half a million patients worldwide and is the most rapidly increasing cause of cancer death in the United States owing to the lack of effective treatment options for advanced disease [1]. Numerous lines of clinical and histopathologic evidence suggest that HCC is a heterogeneous disease, but a coherent molecular explanation for this heterogeneity has yet to be reported [2]. Due to the phenotypic and molecular diversity of HCC, it is a challenge to determine a patient’s prognosis [3]. It would be ideal to increase monitoring of patients with poor prognosis. Thus the inability to accurately predict prognosis leads to excessive or insufficient time spent following patients, resulting in unnecessary anxiety and cost for patients, and inefficient allocation of resources for hospitals.

References

  1. 1.
    El-Serag, H. B., & Rudolph, K. L. (2007). Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557–2576.CrossRefGoogle Scholar
  2. 2.
    Yujin, H., Sebastian, M. B. N., Masahiro, K., et al. (2009). Integrative transcriptone analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Research, 69(18), 7385–7392.CrossRefGoogle Scholar
  3. 3.
    Jean-Charles, N., Aurelien, D. R., Augusto, V., et al. (2013). A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology, 145, 176–187.CrossRefGoogle Scholar
  4. 4.
    Forner, A., Llovet, J. M., & Bruix, J. (2012). Hepatocellular carcinoma. Lancet, 379(1245–125), 5.Google Scholar
  5. 5.
    Marrero, J. A., Fontana, R. J., Barrat, A., et al. (2005). Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology, 41, 707–716.CrossRefGoogle Scholar
  6. 6.
    Roayaie, S., Blume, I. N., Thung, S. N., et al. (2009). A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology, 137, 850–855.CrossRefGoogle Scholar
  7. 7.
    Hoshida, Y., Villaneuva, A., Kobayashi, M., et al. (2008). Gene expression in fixed tissues and outcome in hepatocellular carcinoma. New England Journal of Medicine, 359, 1995–2004.CrossRefGoogle Scholar
  8. 8.
    Villanueva, A., Hoshida, Y., Toffanin, S., et al. (2010). New strategies in hepatocellular carcinoma: Genomic prognostic markers. Clinical Cancer Research, 16, 2688–4694.CrossRefGoogle Scholar
  9. 9.
    Lee, J. S., Chu, I. S., Heo, J., et al. (2004). Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology, 40, 667–676.CrossRefGoogle Scholar
  10. 10.
    Roessler, S., Jia, H. L., Budhu, A., et al. (2010). A unique metastasis gene signature enables prediction of tumour relapse in early-stage hepatocellular carcinoma patients. Cancer Research, 70, 10202–10212.CrossRefGoogle Scholar
  11. 11.
    Lee, J. S., Heo, J., Libbrecht, L., et al. (2006). A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nature Medicine, 12, 410–416.CrossRefGoogle Scholar
  12. 12.
    Boyault, S., Rickman, D. S., de Reynies, A., et al. (2007). Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 45, 42–52.CrossRefGoogle Scholar
  13. 13.
    Villanueva, A., Hoshida, Y., Battison, C., et al. (2011). Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology, 140(1501–1512), e1502.Google Scholar
  14. 14.
    Hoshida, Y., Villanueva, A., Sangiovanni, A., et al. Prognostic gene-expression signature for patients with hepatitis C-Related early stage cirrhosis. Gastroentology.Google Scholar
  15. 15.
    Clavien, P. A., Lesurtel, M., Bossuyt, P. M., et al. (2012). Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report. Lancet Oncology 13, e11–e22.Google Scholar
  16. 16.
    Kudo, M. (2011). Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology, 81(Suppl 1), 50–55.CrossRefGoogle Scholar
  17. 17.
    Albain, K. S., Barlow, W. E., Shak, S., et al. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomized trial. Lancet Oncology, 11, 55–65.CrossRefGoogle Scholar
  18. 18.
    Cardoso, F., Van’t Veer, L., Rutgers, E., et al. (2008). Clinical application of the 70-gene profile: The MINDACT trial. Journal of Clinical Oncology 26, 729–735.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Koh Rui Qi
    • 1
  • Pek Mi Xue Michelle
    • 1
  • Tan Min-Han
    • 1
    Email author
  1. 1.Institute of Bioengineering and NanotechnologySingaporeSingapore

Personalised recommendations